Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4- dimethyl-1<i>H</i>-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase

Li Sun, Chris Liang, Sheri Shirazian, +13

Journal of Medicinal Chemistry

Chemoprevention StrategyWeakly Basic AnaloguesPharmacotherapyPharmaceutical ChemistryTumor Biology +18

Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer

Leora Horn, Ziping Wang, Gang Wu, +19

JAMA Oncology

Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors

Christine M. Lovly, Johannes M. Heuckmann, Elisa de Stanchina, +4

Cancer Research

Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Leora Horn, Jeffrey R. Infante, Karen L. Reckamp, +16

Clinical Cancer Research

Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer

Leora Horn, Jennifer G. Whisenant, Heather A. Wakelee, +20

Journal of Thoracic Oncology

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity

Shem Patyna, Alexander Laird, Dirk B. Mendel, +14

Molecular Cancer Therapeutics

Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment

Irina Lambertz, Candy Kumps, Shana Claeys, +28

Clinical Cancer Research

Design and synthesis of aminopropyl tetrahydroindole-based indolin-2-ones as selective and potent inhibitors of Src and Yes tyrosine kinase

Huiping Guan, Alexander Laird, Robert A. Blake, +2

Bioorganic & Medicinal Chemistry Letters

Combinatorial ChemistryMedicinal ChemistryBiochemistryAminopropyl Tetrahydroindole-based Indolin-2-onesNatural Sciences +8

Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration

Timothy L. Jackson, David S. Boyer, David M. Brown, +8

JAMA Ophthalmology

A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors.

Leora Horn, Jeffrey R. Infante, George R. Blumenschein, +8

Journal of Clinical Oncology

OncologyMedicineMetronomic TherapyPathologyAdvanced Solid Tumors +12